The global preclinical imaging market size is likely to be valued at US$4.7 billion in 2026, and is expected to reach US$6.5 billion by 2033, growing at a CAGR of 4.8% during the forecast period from 2026 to 2033, driven by increasing investments in pharmaceutical and biotechnology R&D, a growing pipeline of drug candidates requiring in vivo imaging for efficacy and safety assessment, and ongoing advancements in preclinical imaging technologies, including molecular imaging, photoacoustic tomography, and magnetic particle imaging, which continue to enhance the role of preclinical imaging in drug discovery and translational research.

Driver - Academic Research Investment and Government Biomedical Research Funding

Government biomedical research funding agencies, including the U.S. National Institutes of Health (NIH), the European Research Council (ERC), the U.K. Medical Research Council (MRC), and similar agencies across Asia Pacific, are key drivers of demand for preclinical imaging systems and related service contracts. Their funding supports purchases by academic research institutions, university medical centers, and government laboratories, where advanced in vivo imaging is essential for studying molecular mechanisms and advancing basic science research.

The increasing adoption of shared preclinical imaging facilities, multi-institutional imaging centers, and national research networks is further boosting demand for these systems. This trend is creating significant opportunities for manufacturers with comprehensive multi-modality imaging portfolios that can meet the diverse needs of collaborative research environments.

Restraint - Specialized Expertise Requirements and Imaging Protocol Complexity

Effective preclinical imaging requires specialized expertise in imaging physics, animal physiology, anesthesia management for small animal imaging, radiotracer chemistry for PET and SPECT applications, and advanced quantitative image analysis. This need for cross-disciplinary skills limits adoption at institutions that lack dedicated preclinical imaging specialists.

Developing multimodal imaging protocols, synthesizing and validating imaging agents, and establishing quantitative image analysis workflows require continuous investment in skilled personnel and supporting infrastructure. These ongoing operational requirements add to the total cost of ownership beyond the initial equipment purchase and can influence institutional investment decisions.

Opportunity - AI-integrated Image Analysis, Cloud Platforms, and Preclinical Imaging Services Growth

Artificial intelligence (AI) and machine learning (ML) are being increasingly integrated into preclinical image analysis to automate tasks such as organ segmentation, tumor volume measurement, molecular uptake quantification, and longitudinal change detection. These technologies reduce the time required for manual image analysis, improve the consistency of quantitative results, and enhance overall research efficiency.

The growing demand for preclinical imaging contract research services is creating significant opportunities for the market. Pharmaceutical and biotechnology companies without in-house imaging infrastructure are increasingly relying on specialized contract research organizations (CROs) for advanced imaging capabilities. This trend is expanding business opportunities for both dedicated preclinical imaging service providers and established CROs that have integrated preclinical imaging into their drug discovery and development service portfolios.

Product Type Insights

Imaging systems are expected to remain the largest product segment in the preclinical imaging market, accounting for nearly 58% of global revenue in 2026. Their dominance is attributed to the high capital cost of advanced platforms such as PET/CT, PET/MRI, micro-MRI, and other multimodal imaging systems, which are widely adopted by pharmaceutical companies, research institutions, and specialized imaging centers.

Software and services are projected to be the fastest-growing product segment during the forecast period. Growth is driven by rising demand for AI-enabled image analysis software, cloud-based image management and collaboration platforms, imaging protocol development services, and preclinical imaging contract research services. These offerings enable organizations to access advanced imaging capabilities without investing in expensive imaging equipment.

Modality Insights

Nuclear molecular imaging, including preclinical PET and SPECT, is expected to dominate the modality segment, accounting for about 32% of the market share in 2026. Its leadership is driven by its ability to provide highly quantitative in vivo assessment of target engagement, drug biodistribution, and translational biomarkers, while enabling direct correlation between preclinical and clinical PET/SPECT studies.

Photoacoustic tomography (PAT) is projected to be the fastest-growing modality during the forecast period. Growth is supported by its ability to provide non-ionizing deep-tissue imaging, real-time visualization of vascular and functional processes, and quantitative tracking of cells and nanoparticles, making it well suited for preclinical research applications that extend beyond the capabilities of conventional imaging modalities.

End-user Insights

Pharmaceutical and biotechnology companies are expected to dominate the end-user segment, accounting for around 45% of market revenue in 2026. Their leadership is supported by substantial investments in preclinical imaging infrastructure to accelerate drug discovery, translational research, and in vivo biomarker evaluation.

Academic and research institutes are projected to be the fastest-growing end-user segment during the forecast period. Growth is driven by increasing government funding for biomedical research and the expansion of preclinical imaging infrastructure at universities and research organizations. For example, the National Preclinical Imaging Centre (NPIC) received €3.4 million (nearly US$4.0 million) from Science Foundation Ireland (SFI) to establish a national preclinical imaging infrastructure supporting academic and biomedical research across multiple institutions.

North America Preclinical Imaging Market Trends

North America is expected to dominate the preclinical imaging market, accounting for about 42% of global revenue in 2026. The region's leadership is driven by the United States' position as the world's largest hub for pharmaceutical and biomedical research, the strong presence of leading preclinical imaging companies such as Bruker, Revvity, and FUJIFILM VisualSonics, and an extensive network of NIH-funded academic institutions and pharmaceutical R&D centers that generate sustained demand for preclinical imaging systems and related services.

U.S. Preclinical Imaging Market Insights

The U.S. is expected to lead the preclinical imaging market, accounting for around 80% of North America's market share in 2026. Its leadership is supported by the National Institutes of Health (NIH), the world's largest public funder of biomedical research, which provides extensive funding for preclinical imaging infrastructure through programs such as R01 research grants, P30 core center grants, and S10 shared instrumentation grants. These initiatives enable research universities, medical schools, and government laboratories to acquire advanced preclinical imaging systems and expand their research capabilities.

Canada Preclinical Imaging Market Insights

Canada is expected to account for nearly 20% of the North American preclinical imaging market in 2026. Market growth is supported by funding from the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council (NSERC), which promote the development of academic preclinical imaging programs. The country's expanding pharmaceutical and biotechnology research ecosystem in Toronto, Montreal, and Vancouver, along with established academic imaging centers such as the Centre for Phenogenomics (TCP) in Toronto and the Montreal Neurological Institute, continues to strengthen demand for advanced preclinical imaging systems and services.

Europe Preclinical Imaging Market Trends

Europe is expected to be the second-largest regional market, accounting for approximately 27% of global revenue in 2026. Market growth is driven by strong pharmaceutical R&D investment, along with funding from the European Research Council (ERC) and national research agencies that support academic preclinical imaging programs. The region also benefits from a well-established preclinical imaging innovation ecosystem, with companies such as MILabs B.V. (Netherlands), Mediso Ltd. (Hungary), MR Solutions (U.K.), Aspect Imaging (Israel), Scintica, and Inviscan Imaging Systems contributing to technological advancements and market expansion.

Germany Preclinical Imaging Market Trends

Germany is expected to lead the European preclinical imaging market, accounting for about 45% of the regional market share in 2026. Its leadership is supported by a strong pharmaceutical and life sciences industry, including major companies such as Bayer, Boehringer Ingelheim, and Merck KGaA. Demand is further reinforced by a robust biomedical research ecosystem comprising institutions such as the German Cancer Research Center (DKFZ), Helmholtz Munich, and leading university medical centers, which generate sustained demand for advanced preclinical imaging systems and related services.

U.K. Preclinical Imaging Market Trends

The U.K. is expected to account for approximately 25% of the European preclinical imaging market in 2026. Market growth is supported by funding from the Medical Research Council (MRC) and the Wellcome Trust, which strengthen academic preclinical imaging programs and research infrastructure. The presence of major pharmaceutical companies such as AstraZeneca and GSK, along with a thriving biotechnology sector that increasingly outsources imaging studies to contract research organizations (CROs), continues to drive demand for preclinical imaging systems and services.

Asia Pacific Preclinical Imaging Market Trends

Asia Pacific is projected to be the fastest-growing regional market during the forecast period. Growth is driven by rising pharmaceutical and biotechnology R&D investments across China, Japan, and South Korea, increasing government funding for life sciences research infrastructure at universities and public research institutes, and the expanding adoption of advanced preclinical imaging technologies. The region is also benefiting from the growing presence of United Imaging Healthcare, which is leveraging its established clinical imaging expertise to expand its footprint in the preclinical imaging market.

China Preclinical Imaging Market Trends

China is expected to dominate the Asia Pacific preclinical imaging market, accounting for around 40% of the regional market share in 2026. Its leadership is driven by rapid growth in pharmaceutical and biotechnology R&D, with a large number of innovative drug developers requiring comprehensive preclinical evaluation. Strong government support through the National Natural Science Foundation of China (NSFC), the Chinese Academy of Sciences (CAS), and the Ministry of Science and Technology, together with the expansion of preclinical research facilities at universities, medical schools, and hospital-affiliated research centers, continues to strengthen market growth.

India Preclinical Imaging Market Trends

India is expected to account for approximately 35% of the Asia Pacific preclinical imaging market in 2026. The market is in a strong growth phase, with adoption concentrated at leading pharmaceutical research centers operated by companies such as Sun Pharmaceutical, Dr. Reddy's Laboratories, Cipla, and Biocon Biologics. Growth is further supported by research activities at major institutions, including the Council of Scientific and Industrial Research (CSIR) and the Indian Council of Medical Research (ICMR), as well as the continued expansion of the country's biotechnology research sector.

The global preclinical imaging market is highly competitive and fragmented, comprising diversified scientific instrument manufacturers, specialized preclinical imaging system developers, imaging reagent and contrast agent suppliers, and software and analytics providers supporting the preclinical imaging workflow. Competition is driven by continuous technological innovation, portfolio expansion, and the ability to address the evolving needs of pharmaceutical companies and research institutions.

Bruker Corporation is a leading participant in the market, offering a comprehensive portfolio that includes BioSpin MRI systems, Skyscan micro-CT platforms, and nuclear imaging solutions for pharmaceutical and academic research applications. MILabs B.V. specializes in ultra-high-resolution SPECT/CT and PET/CT systems, providing advanced molecular imaging capabilities for pharmaceutical research and academic institutions that require high spatial resolution for preclinical studies.

Key Industry Developments:

• In May 2026, Euro-BioImaging and its partners launched a global initiative to develop the PRISM standardized metadata framework for preclinical imaging datasets, aiming to improve data interoperability, reproducibility, and sharing across the research community.
• In September 2025, Revvity, Inc. launched the Living Image™ Synergy AI multimodal analysis software for in vivo imaging researchers. The company introduced a unified, AI-powered platform that enabled seamless analysis of data from optical imaging, microCT, ultrasound, and other modalities, helping researchers reduce data inconsistencies, streamline workflows, improve throughput, enhance reproducibility, and accelerate scientific discovery.